Drilldown: Medicines
More actions
Use the filters below to narrow your results.
generic:
brand:
classes: (Click arrow to add another value)
mechanism:
None (2) ·
5-MeO-DMT is a potent 5-HT1A agonist (greater than 5-HT2A). Distinct from N,N-DMT in producing a more unitive, less visual, often ego-dissolving experience. (1) ·
Active alkaloid is cytisine, a nicotinic acetylcholine receptor agonist. NOT a classical 5-HT2A psychedelic. (1) ·
AMPA receptor antagonist (1) ·
Contains the β-carboline alkaloids harmine, harmaline, and tetrahydroharmine, reversible monoamine oxidase inhibitors (RIMAs) that allow oral DMT to reach the brain. (1) ·
Contains varying amounts of DMT, 5-MeO-DMT, bufotenine, and gramine depending on strain and growing conditions. (1) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) ·
GABA reuptake inhibitor (GAT-1 blocker) (1) ·
GABAA positive allosteric modulator (16) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) ·
GABAA positive allosteric modulator; very long half-life (1) ·
GABAA potentiator (1) ·
GABAA potentiator and direct activator (3) ·
GABAB agonist; GHB receptor agonist (1) ·
Irreversible GABA-T inhibitor (1) ·
Melatonin receptor agonist (2) ·
Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) ·
NMDA antagonist; GABAA potentiator (1) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
Prodrug of phenytoin; sodium channel blocker (1) ·
Root bark contains ~1% N,N-dimethyltryptamine (DMT) and related tryptamines. Oral activity requires MAOI co-administration. (1) ·
Selective GABAA agonist (extrasynaptic delta subunit) (1) ·
Serotonin releaser; sigma-1 agonist (1) ·
Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) ·
Sodium channel blocker (2) ·
Sodium channel blocker; GABAA positive allosteric modulator (1) ·
Sodium channel modulator (1) ·
Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) ·
SV2A ligand (higher affinity than levetiracetam) (1) ·
T-type calcium channel blocker (1)
uses:
starting dose:
preparations:
None (48) ·
Acid/base extraction of fresh young grass for tryptamines; combined with an MAOI (1) ·
Bark/woody stem decocted with a DMT-source plant (''Psychotria viridis'', ''Diplopterys cabrerana'') to make ayahuasca (1) ·
Bright red seeds, traditionally ingested or smoked. Highly toxic, narrow margin between active and lethal (1) ·
Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1) ·
Parotid-gland venom expressed onto a glass plate, dried into a shellac-like resin, vaporized and inhaled (1) ·
Root bark acid/base-extracted for DMT; or as the resurrected ''jurema preta'' brew (decocted with an MAOI such as ''Peganum harmala'') (1)
fda max:
routes:
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 54 results in range #1 to #54.